Age Matters in Alzheimer's Clinical Trials
Discover how patient age significantly impacts treatment outcomes in Alzheimer's disease studies. Our groundbreaking research reveals critical insights for more effective trial design.
In this peer-reviewed study published in the Journal of Alzheimer's Disease, we examined age as a moderator in deep brain stimulation (DBS) clinical trials for probable Alzheimer's disease. Our findings reveal that participants ≥65 years old responded more favorably to DBS treatment than younger participants, who showed significantly faster cognitive decline regardless of treatment assignment.
The data suggests that underlying heterogeneity in AD subtypes may influence clinical outcomes and highlights the importance of age-appropriate subject selection, biomarker confirmation, and genotyping in future studies.
Ready to optimize your Alzheimer's trials for better outcomes? Visit our AD trial solutions page to learn how our expertise can support your research.
This article was originally published in the Journal of Alzheimer's Disease (2021). Authors include Steven D. Targum, Lisa Fosdick, Kristen E. Drake, Paul B. Rosenberg, and colleagues from multiple research institutions.
